Abstract:Circulation Research, Volume 132, Issue 11, Page 1521-1545, May 26, 2023. Epidemiologic studies detected an inverse relationship between HDL (high-density lipoprotein) cholesterol (HDL-C) levels and atherosclerotic cardiovascular disease (ASCVD), identifying HDL-C as a major risk factor for ASCVD and suggesting atheroprotective functions of HDL. However, the role of HDL-C as a mediator of risk for ASCVD has been called into question by the failure of HDL-C–raising drugs to reduce cardiovascular events in clinical trials. Progress in understanding the heterogeneous nature of HDL particles in terms of their protein, lipid, and small RNA composition has contributed to the realization that HDL-C levels do not necessarily reflect HDL function. The most examined atheroprotective function of HDL is reverse cholesterol transport, whereby HDL removes cholesterol from plaque macrophage foam cells and delivers it to the liver for processing and excretion into bile. Indeed, in several studies, HDL has shown inverse associations between HDL cholesterol efflux capacity and ASCVD in humans. Inflammation plays a key role in the pathogenesis of atherosclerosis and vulnerable plaque formation, and a fundamental function of HDL is suppression of inflammatory signaling in macrophages and other cells. Oxidation is also a critical process to ASCVD in promoting atherogenic oxidative modifications of LDL (low-density lipoprotein) and cellular inflammation. HDL and its proteins including apoAI (apolipoprotein AI) and PON1 (paraoxonase 1) prevent cellular oxidative stress and LDL modifications. Importantly, HDL in humans with ASCVD is oxidatively modified rendering HDL dysfunctional and proinflammatory. Modification of HDL with reactive carbonyl species, such as malondialdehyde and isolevuglandins, dramatically impairs the antiatherogenic functions of HDL. Importantly, treatment of murine models of atherosclerosis with scavengers of reactive dicarbonyls improves HDL function and reduces systemic inflammation, atherosclerosis development, and features of plaque instability. Here, we discuss the HDL antiatherogenic functions in relation to oxidative modifications and the potential of reactive dicarbonyl scavengers as a therapeutic approach for ASCVD.

HDL and Immunomodulation: an Emerging Role of HDL Against Atherosclerosis

HDL and immunomodulation: an emerging role of HDL against atherosclerosis.

High-density Lipoprotein Affects Antigen Presentation by Interfering with Lipid Raft: a Promising Anti-Atherogenic Strategy

High-density Lipoprotein and Inflammation and Its Significance to Atherosclerosis

New insights into the emerging effects of inflammatory response on HDL particles structure and function

Interaction between high-density lipoproteins and inflammation: Function matters more than concentration!

HDL suppresses dendritic cell maturation and modulates CD4+ T cell subtypes against inflammatory in a mouse model of rheumatoid arthritis

Progress of High Density Lipoprotein in Resisting Atherosclerosis

HDL Promotes Rapid Atherosclerosis Regression in Mice and Alters Inflammatory Properties of Plaque Monocyte-Derived Cells.

Bridging the Gap Between the Bench and Bedside: Clinical Applications of High-density Lipoprotein Function

HDL and arteriosclerosis: beyond reverse cholesterol transport

HDL Function and Atherosclerosis: Reactive Dicarbonyls as Promising Targets of Therapy

HDL inhibits inflammation by suppressing dendritic cell maturation and modulating CD4+ T cell subtypes in collagen-induced arthritis mice

[Molecular Mechanism and Evaluation Method for Anti-Inflammatory HDL]

Re-understanding the Relationship of High-Density Lipoprotein with Atherosclerosis Vascular Disease

Progress of Cardioprotective Effects of High Density Lipoprotein: Function and Mechanism

[Chronic Inflammation, Autoimmunity and Atherosclerosis].

Oxhdl_3 and Oxldl Induce the Expression of IL-1β,IL-6,HLA-DR,and CD86 in THP-1 Monocyte-Derived Macrophages

A Novel Anti-Inflammatory Mechanism of High Density Lipoprotein Through Up-Regulating Annexin A1 in Vascular Endothelial Cells.

High-density Lipoprotein Increases the Uptake of Oxidized Low Density Lipoprotein Via PPARγ/CD36 Pathway in Inflammatory Adipocytes

Apolipoprotein M likely extends its anti-atherogenesis via anti-inflammation.